Literature DB >> 35864225

CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription.

Liu-Qing Yang1, Han-Yin Hu1, Yao Han1, Ze-Yi Tang1, Jie Gao1, Qi-Yin Zhou1, Yi-Xuan Liu1, Hao-Sa Chen1, Tu-Nan Xu1, Lei Ao1, Ying Xu1, Xuan Che2, Ya-Bo Jiang3, Chun-Wei Xu4, Xian-Chao Zhang5, Yu-Xin Jiang1, Michal Heger1,6,7, Xiao-Min Wang8, Shu-Qun Cheng9,10, Wei-Wei Pan11,12.   

Abstract

Epigenetic alterations have been functionally linked to ovarian cancer development and occurrence. The CXXC zinc finger protein 1 (CFP1) is an epigenetic regulator involved in DNA methylation and histone modification in mammalian cells. However, its role in ovarian cancer cells is unknown. Here, we show that CFP1 protein is highly expressed in human ovarian cancer tissues. Loss of CFP1 inhibited the growth of human ovarian cancer cells, promoted apoptosis, and increased senescence. CFP1 knockdown resulted in reduced levels of SETD1 (a CFP1 partner) and histone H3 trimethylation at the fourth lysine residue (H3K4me3). RNA-sequencing revealed that deletion of CFP1 resulted in mRNA reduction of bone marrow stromal cell antigen 2 (BST2). Bioinformatics analysis and chromatin immunoprecipitation showed that CFP1 binds to the promoter of BST2 and regulates its transcription directly. Overexpression of BST2 rescued the growth inhibitory effect of CFP1 loss. Furthermore, depletion of cullin-RING ubiquitin ligases 4 (CRL4) components ROC1 or CUL4A had significantly inhibited the expression of CFP1 and BST2 similar to MLN4924 treatment that blocked cullin neddylation and inactivated CRL4s. In conclusion, CFP1 promotes ovarian cancer cell proliferation and apoptosis by regulating the transcription of BST2, and the expression of CFP1 was affected by CRL4 ubiquitin ligase complex.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35864225     DOI: 10.1038/s41417-022-00503-z

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  36 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells.

Authors:  Yong Cang; Jianxuan Zhang; Sally A Nicholas; Jayson Bastien; Baojie Li; Pengbo Zhou; Stephen P Goff
Journal:  Cell       Date:  2006-12-01       Impact factor: 41.582

3.  Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study.

Authors:  Chung-Sheng Shi; Kuan-Lin Kuo; Wei-Chou Lin; Mei-Sin Chen; Shing-Hwa Liu; Shih-Ming Liao; Chen-Hsun Hsu; Yu-Wei Chang; Hong-Chiang Chang; Kuo-How Huang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

4.  ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence.

Authors:  Lijun Jia; Maria S Soengas; Yi Sun
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

Review 5.  Real-world evidence in the treatment of ovarian cancer.

Authors:  E A Eisenhauer
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

6.  Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer.

Authors:  Lei Jia; Fan Yan; Wenfeng Cao; Zhengming Chen; Hong Zheng; Haixin Li; Yi Pan; Navneet Narula; Xiubao Ren; Hui Li; Pengbo Zhou
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

7.  Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Authors:  Gina M Mantia-Smaldone; Robert P Edwards; Anda M Vlad
Journal:  Cancer Manag Res       Date:  2010-12-30       Impact factor: 3.989

Review 8.  The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.

Authors:  Youzhou Sang; Fan Yan; Xiubao Ren
Journal:  Oncotarget       Date:  2015-12-15

Review 9.  Anticancer drug discovery by targeting cullin neddylation.

Authors:  Qing Yu; Yihan Jiang; Yi Sun
Journal:  Acta Pharm Sin B       Date:  2019-09-20       Impact factor: 11.413

10.  Comprehensive genomic analysis of microenvironment phenotypes in ovarian cancer.

Authors:  Jingshu Wang; Tingting Zhang; Lina Yang; Gong Yang
Journal:  PeerJ       Date:  2020-11-23       Impact factor: 2.984

View more
  1 in total

1.  Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.

Authors:  Fabio Pastorino; Mario Capasso; Chiara Brignole; Serena Giglio; Veronica Bensa; Sueva Cantalupo; Vito Alessandro Lasorsa; Annalisa Tondo; Rossella Mura; Angela Rita Sementa; Alberto Garaventa; Mirco Ponzoni; Loredana Amoroso
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.